Overview

MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma

Status:
Withdrawn

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

This is a Phase 1b open-label dose escalation trial of Ad/MG1-MAGEA3 and Pembrolizumab in patients with Metastatic Melanoma or Cutaneous Squamous Cell Skin Cancer that has failed prior standard of care treatments. Upon determination of a Maximum Tolerated Dose (MTD) or Maximum Feasible Dose (MFD) the study will be expanded into up to 24 additional Metastatic Melanoma patients.

Phase:

Phase 1

Details

Lead Sponsor:

Turnstone Biologics, Corp.
Turnstone Biologics, Inc.

Treatments:

Cyclophosphamide
Pembrolizumab